相关实验视频

Updated: May 8, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

在患有不稳定胸痛的患者中,通过瘤缩因子-α阻塞调节CD4(+) CD28无 T 淋巴细胞

Vittoria Rizzello¹, Giovanna Liuzzo, Salvatore Brugaletta

¹Cardiology Department, Catholic University, Rome, Italy.

|May 10, 2006

概括

阻断瘤坏死因子-α (TNF-α) 与infliximab在不稳定的心脏病患者中降低了攻击性的CD4(+) CD28无T细胞. 这表明TNF-α阻断可能调节心血管疾病中的炎症.

科学领域:

免疫学免疫学免疫学
心脏病学心脏病学
炎症炎症是一种炎症.

背景情况:

瘤亡因子-α (TNF-α) 促进CD4的扩张(+) CD28无T细胞.
这种T细胞子集与不稳定性胸痛 (UA) 中的侵略性炎症有关.

研究的目的:

调查选择性TNF-α阻断是否可以调节UA患者的炎症.

主要方法:

来自17名UA患者的周围血液与不同剂量的因弗利西马布 (抗TNF-α抗体) 进行了化.
通过流细胞计量分析了CD4 ((+) CD28无T细胞百分比和CD4+T细胞上的CD28表达.

主要成果:

因弗利克西马布显著降低了CD4的百分比(+) CD28无T细胞.
增加的INFLIXIMAB剂量导致CD4+T细胞的CD28表达显著增加.

结论:

选择性TNF-α阻断有效地降低了UA患者的CD4(+) CD28无T细胞扩张的活体扩张.
需要进一步的研究来确定调节CD4 ((+) CD28null T细胞的临床益处.

更多相关视频

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity

Published on: June 7, 2017

An In Vivo Mouse Model to Measure Naïve CD4 T Cell Activation, Proliferation and Th1 Differentiation Induced by Bone Marrow-derived Dendritic Cells

An In Vivo Mouse Model to Measure Naïve CD4 T Cell Activation, Proliferation and Th1 Differentiation Induced by Bone Marrow-derived Dendritic Cells

Published on: August 22, 2018

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...